Akhoundova, Dilara
Fischer, Stefanie
Triscott, Joanna
Lehner, Marika
Thienger, Phillip
Maletti, Sina
Jacquet, Muriel
Lubis, Dinda S.H.
Bubendorf, Lukas
Jochum, Wolfram
Rubin, Mark A.
Funding for this research was provided by:
Nuovo-Soldati Foundation for Cancer Research
Stiktung für klinisch-experimentelle Tumorforschung
ISREC Fondation Recherche Cancer
Werner and Hedy Berger-Janser Foundation
SPHN SOCIB
Article History
Received: 18 April 2024
Accepted: 7 June 2024
First Online: 21 June 2024
Declarations
:
: The study was approved by the local ethics committee (Kantonale Ethikkommission Bern, BASEC ID 2022 − 00978). The patient provided written consent for anonymized use of his clinical data. No identifiable images or data are included in this report. All study procedures were performed in accordance with relevant guidelines, such as such as the Declaration of Helsinki, as well as local regulations. All animal studies were approved by the Cantonal Veterinary Ethical Committee, Switzerland (license BE46/2021).
: Not applicable.
: M.A.R. is a co-inventor on patents in the area for diagnosis and therapy in prostate cancer for ETS fusions (University of Michigan and the Brigham and Women’s Hospital), SPOP mutations (Cornell University), and EZH2 (University of Michigan). S.F. has the following conflicts of interest to declare: Advisory Board – Ipsen (compensated, institutional), Speakers’ bureau – Janssen (compensated, institutional), Travel support – Bayer. D.A. and the rest of the authors declare no conflicts of interests.